Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
[Not Available].

Therapie

Le Louët H, Loupi E, Haramburu F.
PMID: 27393409
Therapie. 2007 May-Jun;62(3):241-4. doi: 10.2515/therapie:2007048.

Le vaccin est un médicament biologique (le plus souvent anti-infectieux) administré dans un but le plus souvent préventif, dont l'effet n'est pas pharmacologique mais immunologique. Il doit être évalué par les techniques habituelles de la pharmacologie clinique et de...

Cite
Le Louët H, Loupi E, Haramburu F. Quelle pharmacovigilance pour les vaccins ? [Not Available]. Therapie. 2007;62(3):241-4doi: 10.2515/therapie:2007048.
Le Louët, H., Loupi, E., Haramburu, F. (2007). Quelle pharmacovigilance pour les vaccins ? [Not Available]. Therapie, 62(3), 241-4. https://doi.org/10.2515/therapie:2007048
Le Louët, Hervé, et al. "Quelle pharmacovigilance pour les vaccins ?" [Not Available]. Therapie vol. 62,3 (2007): 241-4. doi: https://doi.org/10.2515/therapie:2007048
Le Louët H, Loupi E, Haramburu F. Quelle pharmacovigilance pour les vaccins ? [Not Available]. Therapie. 2007 May-Jun;62(3):241-4. doi: 10.2515/therapie:2007048. French. PMID: 27393409.
Copy Download .nbib Format: NLM
Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.

RMD open

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P.
PMID: 29071117
RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017.

BACKGROUND: The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN pathway genes such as IFN regulatory factor 5 and...

Cite
Juge PA, Gazal S, Constantin A, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017;3(2):e000448doi: 10.1136/rmdopen-2017-000448.
Juge, P. A., Gazal, S., Constantin, A., Mariette, X., Combe, B., Tebib, J., Dougados, M., Sibilia, J., Le Loet, X., & Dieudé, P. (2017). Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD open, 3(2), e000448. https://doi.org/10.1136/rmdopen-2017-000448
Juge, Pierre-Antoine, et al. "Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis." RMD open vol. 3,2 (2017): e000448. doi: https://doi.org/10.1136/rmdopen-2017-000448
Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017. PMID: 29071117; PMCID: PMC5640092.
Copy Download .nbib Format: NLM
Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet.

Expert review of clinical pharmacology

Hoffmann M, Vander Stichele R, Bates DW, Björklund J, Alexander S, Andersson ML, Auraaen A, Bennie M, Dahl ML, Eiermann B, Hackl W, Hammar T, Hjemdahl P, Koch S, Kunnamo I, Le Louët H, Panagiotis P, Rägo L, Spedding M, Seidling HM, Demner-Fushman D, Gustafsson LL.
PMID: 32990065
Expert Rev Clin Pharmacol. 2020 Sep;13(9):925-934. doi: 10.1080/17512433.2020.1805314. Epub 2020 Sep 29.

INTRODUCTION: Technical and logical breakthroughs have provided new opportunities in medicine to use knowledge bases and large-scale clinical data (real-world) at point-of-care as part of a learning healthcare system to diminish the knowledge-practice gap.AREAS COVERED: The article is based...

Cite
Hoffmann M, Vander Stichele R, Bates DW, et al. Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Rev Clin Pharmacol. 2020;13(9):925-934doi: 10.1080/17512433.2020.1805314.
Hoffmann, M., Vander Stichele, R., Bates, D. W., Björklund, J., Alexander, S., Andersson, M. L., Auraaen, A., Bennie, M., Dahl, M. L., Eiermann, B., Hackl, W., Hammar, T., Hjemdahl, P., Koch, S., Kunnamo, I., Le Louët, H., Panagiotis, P., Rägo, L., Spedding, M., Seidling, H. M., Demner-Fushman, D., & Gustafsson, L. L. (2020). Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert review of clinical pharmacology, 13(9), 925-934. https://doi.org/10.1080/17512433.2020.1805314
Hoffmann, Mikael, et al. "Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet." Expert review of clinical pharmacology vol. 13,9 (2020): 925-934. doi: https://doi.org/10.1080/17512433.2020.1805314
Hoffmann M, Vander Stichele R, Bates DW, Björklund J, Alexander S, Andersson ML, Auraaen A, Bennie M, Dahl ML, Eiermann B, Hackl W, Hammar T, Hjemdahl P, Koch S, Kunnamo I, Le Louët H, Panagiotis P, Rägo L, Spedding M, Seidling HM, Demner-Fushman D, Gustafsson LL. Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Rev Clin Pharmacol. 2020 Sep;13(9):925-934. doi: 10.1080/17512433.2020.1805314. Epub 2020 Sep 29. PMID: 32990065.
Copy Download .nbib Format: NLM
Fish mislabelling in France: substitution rates and retail types.

PeerJ

Bénard-Capelle J, Guillonneau V, Nouvian C, Fournier N, Le Loët K, Dettai A.
PMID: 28462014
PeerJ. 2015 Jan 06;2:e714. doi: 10.7717/peerj.714. eCollection 2015.

Market policies have profound implications for consumers as well as for the management of resources. One of the major concerns in fish trading is species mislabelling: the commercial name used does not correspond to the product, most often because...

Cite
Bénard-Capelle J, Guillonneau V, Nouvian C, et al. Fish mislabelling in France: substitution rates and retail types. PeerJ. 2015;2:e714doi: 10.7717/peerj.714.
Bénard-Capelle, J., Guillonneau, V., Nouvian, C., Fournier, N., Le Loët, K., & Dettai, A. (2015). Fish mislabelling in France: substitution rates and retail types. PeerJ, 2e714. https://doi.org/10.7717/peerj.714
Bénard-Capelle, Julien, et al. "Fish mislabelling in France: substitution rates and retail types." PeerJ vol. 2 (2015): e714. doi: https://doi.org/10.7717/peerj.714
Bénard-Capelle J, Guillonneau V, Nouvian C, Fournier N, Le Loët K, Dettai A. Fish mislabelling in France: substitution rates and retail types. PeerJ. 2015 Jan 06;2:e714. doi: 10.7717/peerj.714. eCollection 2015. PMID: 28462014; PMCID: PMC5407283.
Copy Download .nbib Format: NLM
Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.

RMD open

Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B.
PMID: 27252898
RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016.

INTRODUCTION: Use of prediction matrices of risk or rapid radiographic progression (RRP) for early rheumatoid arthritis (RA) in clinical practice could help to better rationalise the first line of treatment. Before use, they must be validated in populations that...

Cite
Granger B, Combe B, Le Loet X, et al. Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. RMD Open. 2016;2(1):e000245doi: 10.1136/rmdopen-2016-000245.
Granger, B., Combe, B., Le Loet, X., Saraux, A., Guillemin, F., & Fautrel, B. (2016). Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. RMD open, 2(1), e000245. https://doi.org/10.1136/rmdopen-2016-000245
Granger, Benjamin, et al. "Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data." RMD open vol. 2,1 (2016): e000245. doi: https://doi.org/10.1136/rmdopen-2016-000245
Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B. Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016. PMID: 27252898; PMCID: PMC4879338.
Copy Download .nbib Format: NLM
Which Pharmacovigilance for Vaccines?.

Therapie

Le Louët H, Loupi E, Haramburu F.
PMID: 27393410
Therapie. 2007 May-Jun;62(3):245-7. doi: 10.2515/therapie:2007039.

Vaccines are not separate health products but anti-infectious medicines administered for the large part prophylactically and for which the effect is immunological and not pharmacological. They should be evaluated by the usual methods of clinical pharmacology and pharmacovigilance, taking...

Cite
Le Louët H, Loupi E, Haramburu F. Which Pharmacovigilance for Vaccines?. Therapie. 2007;62(3):245-7doi: 10.2515/therapie:2007039.
Le Louët, H., Loupi, E., Haramburu, F. (2007). Which Pharmacovigilance for Vaccines?. Therapie, 62(3), 245-7. https://doi.org/10.2515/therapie:2007039
Le Louët, Hervé, et al. "Which Pharmacovigilance for Vaccines?." Therapie vol. 62,3 (2007): 245-7. doi: https://doi.org/10.2515/therapie:2007039
Le Louët H, Loupi E, Haramburu F. Which Pharmacovigilance for Vaccines?. Therapie. 2007 May-Jun;62(3):245-7. doi: 10.2515/therapie:2007039. PMID: 27393410.
Copy Download .nbib Format: NLM
Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing .

Frontiers in immunology

Brevet P, Lattard C, Guillou C, Rottenberg P, Fardellone P, Le-Loët X, Lequerré T, Cosette P, Boyer O, Fréret M, Vittecoq O.
PMID: 34691039
Front Immunol. 2021 Oct 07;12:733511. doi: 10.3389/fimmu.2021.733511. eCollection 2021.

To identify the targets recognized by anti-carbamylated protein antibodies (anti-CarP) in patients with early Rheumatoid Arthritis (RA), to study the cross-reactivity between anti-CarP and anti-citrullinated protein antibodies (ACPA) and to evaluate their prognostic value. 331 patients (184 RA and...

Cite
Brevet P, Lattard C, Guillou C, et al. Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing . Front Immunol. 2021;12:733511doi: 10.3389/fimmu.2021.733511.
Brevet, P., Lattard, C., Guillou, C., Rottenberg, P., Fardellone, P., Le-Loët, X., Lequerré, T., Cosette, P., Boyer, O., Fréret, M., & Vittecoq, O. (2021). Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing . Frontiers in immunology, 12733511. https://doi.org/10.3389/fimmu.2021.733511
Brevet, Pauline, et al. "Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing ." Frontiers in immunology vol. 12 (2021): 733511. doi: https://doi.org/10.3389/fimmu.2021.733511
Brevet P, Lattard C, Guillou C, Rottenberg P, Fardellone P, Le-Loët X, Lequerré T, Cosette P, Boyer O, Fréret M, Vittecoq O. Anti-Carbamylated Fibrinogen Antibodies Might Be Associated With a Specific Rheumatoid Phenotype and Include a Subset Recognizing . Front Immunol. 2021 Oct 07;12:733511. doi: 10.3389/fimmu.2021.733511. eCollection 2021. PMID: 34691039; PMCID: PMC8529038.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries